22.08.23|Sophie ShulmanThe pharmaceutical company has reached a compromise after being suspected of price-fixing with other generic drug manufacturers in the US. In the first four years, it will pay $22.5 million and in 2028 - $135 million. In addition, the company will donate two drugs worth $50 million to humanitarian organizations
22.11.22|Sophie ShulmanKare Schultz, who served as CEO of the pharmaceutical company for the past five years, has left the company a year early after amassing a salary of more than $100 million. His replacement, Richard Francis, is taking over with less debt and less legal issues, but with the big challenge of creating new growth engines
30.04.18|Amarelle WenkertIn 2017, Israeli-founded SteadyMed won a patent war against United Therapeutics